Adding a second HER2 blocker may lower chance of invasive breast cancer for some women

(American Society of Clinical Oncology) A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news